Data as of Apr 15
| -0.35 / -2.26%|
The 3 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 24.00, with a high estimate of 35.00 and a low estimate of 21.00. The median estimate represents a +58.52% increase from the last price of 15.14.
The current consensus among 3 polled investment analysts is to Buy stock in Cancer Genetics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.